Novartis AG vs T-Mobile Us Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while T-Mobile Us Inc trades at $190.56 (market cap $211.72B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | TMUS | |
|---|---|---|
Market Cap | $290.25B | $211.72B |
Sector | Health | Media |
52-Week High | $168.62 | $259.01 |
52-Week Low | $113.50 | $167.65 |
Enterprise Value | $330.27B | $329.42B |
Dividend Yield | 3.17% | 2.09% |
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →